Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China

References

• Holloway R, Rasmussen SA, Zaza S, et al. Updated preparedness and response framework for influenza pandemics. MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and reports/Centers for Disease Control. 2014;63(RR–06):1–18.
   PubMed Web of Science ®Google Scholar
• Gostin LO, Phelan A, Stoto MA, et al. Virus sharing, genetic sequencing, and global health security. Science. 2014;345(6202):1295–1296.
   PubMed Web of Science ®Google Scholar
• Group WHOW, Ampofo WK, Baylor N, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi Viruses 2012;6(2):142-152, e141-145.
   Web of Science ®Google Scholar
• Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010;28(Suppl 4):D45–D53.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Influenza-associated pediatric deaths–United States, September 2010-August 2011. MMWR Morb Mortal Wkly Rep. 2011;60(36):1233–1238.
   PubMedGoogle Scholar
• Esposito S, Cantarutti L, Molteni CG, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect. 2011;62(5):379–387.
   PubMed Web of Science ®Google Scholar
• Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis. 2012;205(6):895–905.
   PubMed Web of Science ®Google Scholar
• Barria MI, Garrido JL, Stein C, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 2013;207(1):115–124.
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for Influenza vaccines (CPMP/BWP/214/96). [Internet]. 1997. Available from: http://www.eudra.org/emea.htm
   Google Scholar
• Burki F, Sibalin M. Evaluation of influenza vaccine potency by means of a standardized hemagglutination inhibition test. Dev Biol Stand. 1974;26:42–48.
   PubMedGoogle Scholar
• China Food and Drug Administration (CFDA). The Standard guidelines for adverse reactions grading of vaccine clinical trials. [Internet]. 2016. Available from: http://www.sda.gov.cn/WS01/CL1616/83435.html
   Google Scholar
• Wang L, Chandrasekaran V, Domachowske JB, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6-35 months of age during 2013-2014: results from a phase II randomized trial. J Pediatric Infect Dis Soc. 2016;5(2):170–179.
   PubMed Web of Science ®Google Scholar
• Tsurudome Y, Kimachi K, Okada Y, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. Microbiol Immunol. 2015;59(10):597–604.
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang L, Aggarwal N, et al. Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012-2013: a randomized, double-blind, controlled, multicenter, multicountry, clinical trial. J Pediatric Infect Dis Soc. 2015;4(3):242–251.
   PubMed Web of Science ®Google Scholar
• Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >/=18 years: a phase III, randomized trial. Vaccine. 2014;32(13):1480–1487.
   PubMed Web of Science ®Google Scholar
• Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–553.
   PubMed Web of Science ®Google Scholar
• Kieninger D, Sheldon E, Lin WY, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >/=18 years. BMC Infect Dis. 2013;13:343.
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207(12):1878–1887.
   PubMed Web of Science ®Google Scholar
• Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013;13:224.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama. 2003;289(2):179–186.
   PubMed Web of Science ®Google Scholar
• Gaunt ER, Harvala H, McIntyre C, et al. Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model. J Clin Virol. 2011;52(3):215–221.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Coelingh K, Ambrose CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28(9):2149–2156.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Chit A, Hallett D, et al. Effect of influenza vaccines against mismatched strains: a systematic review protocol. Syst Rev. 2012;1:35.
   PubMedGoogle Scholar
• Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009;199(2):159–167.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013–2014 northern hemisphere influenza season. Weekly Epidemiological Record. 2013;88(10):101–114.
   PubMedGoogle Scholar
• Reed C, Meltzer MI, Finelli L, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30(11):1993–1998.
   PubMed Web of Science ®Google Scholar